Post-ischaemic silencing of p66Shc reduces ischaemia/reperfusion brain injury and its expression correlates to clinical outcome in stroke

European Heart Journal

Volumn 36, Issue 25, 2015, Pages 1590-1600

  Spescha, R D ^a   Klohs, J ^b   Semerano, A ^c   Giacalone, G ^c   Derungs, R S ^a   Reiner, M F ^a   Gutierrez, D Rodriguez ^a   Mendez Carmona, N ^a   Glanzmann, M ^a   Savarese, G ^a   Krankel N ^a,d   Akhmedov, A ^a   Keller, S ^a   Mocharla, P ^a   Kaufmann, M R ^a   Wenger, R H ^a   Vogel, J ^a   Kulic, L ^a   Nitsch, R M ^a   Beer, J H ^e   Peruzzotti Jametti, L ^c   Sessa, M ^c   Luscher T F ^a,f   Camici, G G ^a   more..

^a UNIVERSITY OF ZURICH   (Switzerland)

^b Institute for Biomedical Engineering   (Switzerland)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e Cantonal Hospital Baden   (Switzerland)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Endothelium; Free radicals; Ischaemia; Reperfusion; Stroke

Indexed keywords

CD45 ANTIGEN; CLAUDIN 5; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; NITRIC OXIDE; PROTEIN P66; PROTEIN P66 SHC; PROTEIN SHC; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN; SHC1 PROTEIN, HUMAN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY ENDOTHELIAL CELL; BRAIN INFARCTION SIZE; BRAIN INJURY; BRAIN ISCHEMIA; CELL HYPOXIA; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIFFUSION WEIGHTED IMAGING; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REOXYGENATION; REPERFUSION INJURY; ANALYSIS OF VARIANCE; ANIMAL; BRAIN INJURIES; C57BL MOUSE; CASE CONTROL STUDY; CELL CULTURE; CEREBRAL ARTERY DISEASE; DRUG EFFECTS; ENDOTHELIUM CELL; GENETICS; ISCHEMIC POSTCONDITIONING; METABOLISM; MICROCIRCULATION; MIDDLE AGED; PHYSIOLOGY; PROCEDURES; STROKE; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN INJURIES; CASE-CONTROL STUDIES; CELLS, CULTURED; CLAUDIN-5; ENDOTHELIAL CELLS; FEMALE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; ISCHEMIC POSTCONDITIONING; MALE; MICE, INBRED C57BL; MICROCIRCULATION; MIDDLE AGED; REACTIVE OXYGEN SPECIES; REPERFUSION INJURY; RNA, MESSENGER; RNA, SMALL INTERFERING; SHC SIGNALING ADAPTOR PROTEINS; STROKE; TREATMENT OUTCOME;

EID: 84937213794     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv140     Document Type: Article

References (50)

1. Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe 2014: Epidemiological update. Eur Heart J 2014;35:2950-2959.
2. O'Collins VE, MacLeod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1, 026 experimental treatments in acute stroke. Ann Neurol 2006;59:467-477.
3. Fisher M, Feuerstein G, HowellsDW, Hurn PD, Kent TA, Savitz SI, Lo EH, Group S. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009;40:2244-2250.
4. Spescha RD, Sessa M, Camici GG. Angiopoietin-like 4 and ischaemic stroke: A promising start. Eur Heart J 2013;34:3603-3605.
5. Tissue plasminogen activator for acute ischemic stroke. The national institute of neurological disorders and stroke RT-PA stroke study group. N Engl J Med 1995; 333:1581-1587.
6. Obermeier B, Daneman R, Ransohoff RM. Development, maintenance and disruption of the blood-brain barrier. Nat Med 2013;19:1584-1596.
7. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008;57:178-201.
8. Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat Med 2011;17:796-808.
9. Su EJ, Fredriksson L, Geyer M, Folestad E, Cale J, Andrae J, Gao Y, Pietras K, Mann K, Yepes M, Strickland DK, Betsholtz C, Eriksson U, Lawrence DA. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med 2008;14:731-737.
10. Lo EH, Dalkara T, Moskowitz MA. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 2003;4:399-415.
11. Rodrigues SF, Granger DN. Role of blood cells in ischaemia-reperfusion induced endothelial barrier failure. Cardiovasc Res 2010;87:291-299.
12. Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron 2010;67:181-198.
13. Pelicci G, Lanfrancone L, Grignani F, McGlade J, Cavallo F, Forni G, Nicoletti I, Grignani F, Pawson T, Pelicci PG. A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell 1992;70:93-104.
14. Migliaccio E, Mele S, Salcini AE, Pelicci G, Lai KM, Superti-Furga G, Pawson T, Di-Fiore PP, Lanfrancone L, Pelicci PG. Opposite effects of the p52shc/p46shc and p66shc splicing isoforms on the EGF receptor-MAP kinase-fos signalling pathway. EMBO J 1997;16:706-716.
15. Camici GG, Schiavoni M, Francia P, Bachschmid M, Martin-Padura I, Hersberger M, Tanner FC, Pelicci P, Volpe M, Anversa P, Luscher TF, Cosentino F. Genetic deletion of p66(Shc) adaptor protein prevents hyperglycemia-induced endothelial dysfunction and oxidative stress. Proc Natl Acad Sci USA 2007;104:5217-5222.
16. Francia P, delli Gatti C, Bachschmid M, Martin-Padura I, Savoia C, Migliaccio E, Pelicci PG, Schiavoni M, Luscher TF, Volpe M, Cosentino F. Deletion of p66shc gene protects against age-related endothelial dysfunction. Circulation 2004;110: 2889-2895.
17. Napoli C, Martin-Padura I, de Nigris F, Giorgio M, Mansueto G, Somma P, Condorelli M, Sica G, De Rosa G, Pelicci P. Deletion of the p66Shc longevity gene reduces systemic and tissue oxidative stress, vascular cell apoptosis, and early atherogenesis in mice fed a high-fat diet. Proc Natl Acad Sci USA 2003;100:2112-2116.
18. Zaccagnini G, Martelli F, Fasanaro P, Magenta A, Gaetano C, Di Carlo A, Biglioli P, Giorgio M, Martin-Padura I, Pelicci PG, Capogrossi MC. p66ShcA modulates tissue response to hindlimb ischemia. Circulation 2004;109:2917-2923.
19. Francia P, Cosentino F, Schiavoni M, Huang Y, Perna E, Camici GG, Luscher TF, Volpe M. p66(Shc) protein, oxidative stress, and cardiovascular complications of diabetes: The missing link. J Mol Med 2009;87:885-891.
20. Camici GG, ShiY, Cosentino F, Francia P, Luscher TF. Anti-aging medicine: molecular basis for endothelial cell-targeted strategies - A mini-review. Gerontology 2011;57: 101-108.
21. Cosentino F, Francia P, Camici GG, Pelicci PG, Luscher TF, Volpe M. Final common molecular pathways of aging and cardiovascular disease: Role of the p66Shc protein. Arterioscler Thromb Vasc Biol 2008;28:622-628.
22. Spescha RD, Shi Y, Wegener S, Keller S, Weber B, Wyss MM, Lauinger N, Tabatabai G, Paneni F, Cosentino F, Hock C, Weller M, Nitsch RM, Luscher TF, Camici GG. Deletion of the ageing gene p66(Shc) reduces early stroke size following ischaemia/reperfusion brain injury. Eur Heart J 2013;34:96-103.
23. Pagnin E, Fadini G, de Toni R, Tiengo A, Calo L, Avogaro A. Diabetes induces p66shc gene expression in human peripheral blood mononuclear cells: Relationship to oxidative stress. J Clin Endocrinol Metab 2005;90:1130-1136.
24. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991;337: 1521-1526.
25. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24: 35-41.
26. Franzeck FC, Hof D, Spescha RD, Hasun M, Akhmedov A, Steffel J, ShiY, Cosentino F, Tanner FC, von Eckardstein A, MaierW, Luscher TF, Wyss CA, Camici GG. Expression of the aging gene p66Shc is increased in peripheral blood monocytes of patients with acute coronary syndrome but not with stable coronary artery disease. Atherosclerosis 2012;220:282-286.
27. Paneni F, Mocharla P, Akhmedov A, Costantino S, Osto E, Volpe M, Luscher TF, Cosentino F. Gene silencing of the mitochondrial adaptor p66(Shc) suppresses vascular hyperglycemic memory in diabetes. Circ Res 2012;111:278-289.
28. Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C, Sharp FR. A semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab 1990;10:290-293.
29. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: Evaluation of the model and development of a neurologic examination. Stroke 1986;17:472-476.
30. Gursoy-Ozdemir Y, Bolay H, Saribas O, Dalkara T. Role of endothelial nitric oxide generation and peroxynitrite formation in reperfusion injury after focal cerebral ischemia. Stroke 2000;31:1974-1980; discussion 1981.
31. Bouleti C, Mathivet T, Coqueran B, Serfaty JM, Lesage M, Berland E, Ardidie-Robouant C, Kauffenstein G, Henrion D, Lapergue B, Mazighi M, Duyckaerts C, Thurston G, Valenzuela DM, Murphy AJ, Yancopoulos GD, Monnot C, Margaill I, Germain S. Protective effects of angiopoietin-like 4 oncerebrovascular and functional damages in ischaemic stroke. Eur Heart J 2013;34: 3657-3668.
32. Spescha RD, Glanzmann M, Simic B, Witassek F, Keller S, Akhmedov A, Tanner FC, Luscher TF, Camici GG. Adaptor protein p66Shc mediates hypertension-associated, cyclic stretch-dependent, endothelial damage. Hypertension 2014;64:347-353.
33. Besler C, Heinrich K, Rohrer L, Doerries C, Riwanto M, Shih DM, Chroni A, Yonekawa K, Stein S, Schaefer N, Mueller M, Akhmedov A, Daniil G, Manes C, Templin C, Wyss C, Maier W, Tanner FC, Matter CM, Corti R, Furlong C, Lusis AJ, von Eckardstein A, Fogelman AM, Luscher TF, Landmesser U. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest 2011;121:2693-2708.
34. Shi Y, Cosentino F, Camici GG, Akhmedov A, Vanhoutte PM, Tanner FC, Luscher TF. Oxidized low-density lipoprotein activates p66Shc via lectin-like oxidized lowdensity lipoprotein receptor-1, protein kinase C-beta, and c-Jun N-terminal kinase kinase in human endothelial cells. Arterioscler Thromb Vasc Biol 2011;31:2090-2097.
35. Cecchelli R, Berezowski V, Lundquist S, Culot M, Renftel M, Dehouck MP, Fenart L. Modelling of the blood-brain barrier in drug discovery and development. Nat Rev Drug Discov 2007;6:650-661.
36. Walchli T, Pernet V, Weinmann O, Shiu JY, Guzik-Kornacka A, Decrey G, Yuksel D, Schneider H, Vogel J, Ingber DE, Vogel V, Frei K, Schwab ME. Nogo-A is a negative regulator of CNS angiogenesis. Proc Natl Acad Sci USA 2013;110:E1943-E1952.
37. Migliaccio E, Giorgio M, Mele S, Pelicci G, Reboldi P, Pandolfi PP, Lanfrancone L, Pelicci PG. The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature 1999;402:309-313.
38. Drummond GR, Selemidis S, Griendling KK, Sobey CG. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov 2011;10:453-471.
39. Tomilov AA, Bicocca V, Schoenfeld RA, Giorgio M, Migliaccio E, Ramsey JJ, Hagopian K, Pelicci PG, Cortopassi GA. Decreased superoxide production in macrophages of long-lived p66Shc knock-out mice. J Biol Chem 2010;285:1153-1165.
40. Zehendner CM, Librizzi L, Hedrich J, Bauer NM, Angamo EA, de Curtis M, Luhmann HJ. Moderate hypoxia followed by reoxygenation results in blood-brain barrier breakdown via oxidative stress-dependent tight-junction protein disruption. PLoS ONE 2013;8:e82823.
41. Heumuller S, Wind S, Barbosa-Sicard E, Schmidt HH, Busse R, Schroder K, Brandes RP. Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. Hypertension 2008;51:211-217.
42. Mello CC, Conte D Jr. Revealing the world of RNA interference. Nature 2004;431: 338-342.
43. Kanasty R, Dorkin JR, Vegas A, Anderson D. Delivery materials for siRNA therapeutics. Nat Mater 2013;12:967-977.
44. Astrup J, Symon L, Branston NM, Lassen NA. Cortical evoked potential and extracellular K+ and H+ at critical levels of brain ischemia. Stroke 1977;8:51-57.
45. Yepes M, Sandkvist M, Moore EG, Bugge TH, Strickland DK, Lawrence DA. Tissuetype plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest 2003;112:1533-1540.
46. Zhao WY, Han S, Zhang L, Zhu YH, Wang LM, Zeng L. Mitochondria-targeted antioxidant peptide SS31 prevents hypoxia/reoxygenation-induced apoptosis by downregulating p66Shc in renal tubular epithelial cells. Cell Physiol Biochem 2013;32: 591-600.
47. Dalkara T, Yoshida T, Irikura K, Moskowitz MA. Dual role of nitric oxide in focal cerebral ischemia. Neuropharmacology 1994;33:1447-1452.
48. Schreibelt G, Kooij G, Reijerkerk A, van Doorn R, Gringhuis SI, van der Pol S, Weksler BB, Romero IA, Couraud PO, Piontek J, Blasig IE, Dijkstra CD, Ronken E, de Vries HE. Reactive oxygen species alter brain endothelial tight junction dynamics via RhoA, PI3 kinase, and PKB signaling. FASEB J 2007;21:3666-3676.
49. Kastrup A, Groschel K, Ringer TM, Redecker C, Cordesmeyer R, Witte OW, Terborg C. Early disruption of the blood-brain barrier after thrombolytic therapy predicts hemorrhage in patients with acute stroke. Stroke 2008;39:2385-2387.
50. Kochanek PM, Hallenbeck JM. Polymorphonuclear leukocytes and monocytes/macrophages in the pathogenesis of cerebral ischemia and stroke. Stroke 1992;23: 1367-1379.